Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 1/20 | 0.79 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.79 |
| ▸ | FFAR1 | O14842 | 4/20 | 0.70 |
| ▸ | S1PR4 | O95977 | 2/20 | 0.70 |
| ▸ | S1PR1 | P21453 | 2/20 | 0.70 |
| ▸ | S1PR3 | Q99500 | 2/20 | 0.70 |
| ▸ | PLA2G4B | P0C869 | 7/20 | 0.65 |
| ▸ | S1PR5 | Q9H228 | 1/20 | 0.64 |
| ▸ | TP53 | P04637 | 1/20 | 0.62 |
| ▸ | TSHR | P16473 | 1/20 | 0.62 |
| ▸ | FFAR4 | Q5NUL3 | 1/20 | 0.59 |
| ▸ | THRA | P10827 | 1/20 | 0.59 |
| ▸ | THRB | P10828 | 1/20 | 0.59 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3488457 | 1.00 | LMNA (0.79) | LMNAL3MBTL1FFAR1S1PR4S1PR1 | |
| SCHEMBL17320238 | 1.00 | LMNA (0.79) | LMNAL3MBTL1FFAR1S1PR4S1PR1 | |
| SCHEMBL2183912 | 1.00 | LMNA (0.79) | LMNAL3MBTL1FFAR1S1PR4S1PR1 | |
| SCHEMBL6496565 | 1.00 | LMNA (0.79) | LMNAL3MBTL1FFAR1S1PR4S1PR1 | |
| SCHEMBL6497674 | 1.00 | LMNA (0.79) | LMNAL3MBTL1FFAR1S1PR4S1PR1 | |
| SCHEMBL8558255 | 1.00 | LMNA (0.79) | LMNAL3MBTL1FFAR1S1PR4S1PR1 | |
| SCHEMBL8378949 | 1.00 | LMNA (0.79) | LMNAL3MBTL1FFAR1S1PR4S1PR1 | |
| Hydrochloric Acid SCHEMBL10803998 | 0.98 | LMNA (0.77) | LMNAL3MBTL1FFAR1S1PR4S1PR1 | |
| SCHEMBL24723561 | 0.98 | L3MBTL1 (0.82) | LMNAL3MBTL1FFAR1S1PR4S1PR1 | |
| Hydrochloric Acid SCHEMBL10807470 | 0.97 | L3MBTL1 (0.79) | LMNAL3MBTL1FFAR1S1PR4S1PR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2343306-B1 | Glycolipid derivatives, process for production of the same, intermediates for synthesis thereof, and process for production of the intermediates | JAPAN PRESIDENT NAT CT NEUROLOGY & PSYCHIATRY (JP) | 2018-04-04 | — | — | EP | disclosed |
| US-8034908-B2 | Glycolipids and synthetic method thereof as well as their synthetic intermediates, and synthetic method thereof | JAPAN AS REPRESENTED BY PRESIDENT OF NATIONAL CENTER OF NEUROLOGY AND PSYCHIATRY (JP) | 2011-10-11 | — | — | US | disclosed |
| EP-2343306-A1 | Glycolipid derivatives, process for production of the same, intermediates for synthesis thereof, and process for production of the intermediates | Japan as represented by President of National Center of Neurology and Psychiatry Ministry of Health (JP) | 2011-07-13 | — | — | EP | disclosed |
| US-20100210828-A1 | NEW GLYCOLIPIDS AND SYNTHETIC METHOD THEREOF AS WELL AS THEIR SYNTHETIC INTERMEDIATES, AND SYNTHETIC METHOD THEREOF | JAPAN AS REPRESENTED BY THE PRESIDENT OF NATIONAL CENTER OF NEUROLOGY AND PSYCHIATRY (JP) | 2010-08-19 | — | — | US | disclosed |
| US-7732583-B2 | Glycolipids and synthetic method thereof as well as their synthetic intermediates, and synthetic intermediates, and synthetic method thereof | JAPAN AS REPRESENTED BY PRESIDENT OF NATIONAL CENTER OF NEUROLOGY AND PSYCHIATRY (JP) | 2010-06-08 | — | — | US | disclosed |
| US-20060074235-A1 | Glycolipids derivatives, process for production of the same, intermediates for synthesis thereof, and process for production of the intermediates | JAPAN AS REPRESENTED BY PRESIDENT OF NATIONAL CENTER OF NEUROLOGY AND PSYCHIATRY (JP) | 2006-04-06 | — | — | US | disclosed |
| EP-1619199-A1 | GLYCOLIPID DERIVATIVES, PROCESS FOR PRODUCTION OF THE SAME, INTERMEDIATES FOR SYNTHESIS THEREOF, AND PROCESS FOR PRODUCTION OF THE INTERMEDIATES | Daiichi Asubio Pharma Co., Ltd. (JP) | 2006-01-25 | — | — | EP | disclosed |
| CN-1040541-C | Polypeptide compound and process for preparation thereof | FUJISAWA PHARMACEUTICAL CO (JP) | 1998-11-04 | — | — | CN | disclosed |
| US-H1638-H | CYCLIC HEXAPEPTIDE | FURUTA TAKAHISA (JP) | 1997-03-04 | — | — | US | disclosed |
| EP-0462531-B1 | Cyclic polypeptide with antibiotic activity, process for its preparation and pure culture of a Coelomycetes strain | FUJISAWA PHARMACEUTICAL CO (JP) | 1996-10-02 | — | — | EP | disclosed |
| EP-0729974-A1 | Cyclic polypeptide with antibiotic activity and a process for preparation thereof | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 1996-09-04 | — | — | EP | disclosed |
| US-5376634-A | Microbiocides | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 1994-12-27 | — | — | US | disclosed |
| EP-0486011-A2 | Pharmaceutical composition against Pneumocystis carinii | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 1992-05-20 | — | — | EP | disclosed |
| CN-1059729-A | Novel polypeptide compound and preparation method thereof | FUJISAWA PHARMACEUTICAL CO (JP) | 1992-03-25 | — | — | CN | disclosed |
| EP-0462531-A2 | Cyclic polypeptide with antibiotic activity, process for its preparation and pure culture of a Coelomycetes strain | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 1991-12-27 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100210828-A1 | NEW GLYCOLIPIDS AND SYNTHETIC METHOD THEREOF AS WELL AS THEIR SYNTHETIC INTERMEDIATES, AND SYNTHETIC METHOD THEREOF | SGMS1, UGCG, SGMS2 | LMNA 2012/4885L3MBTL1 1262/4885FFAR1 146/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.